Quinn Opportunity Partners’s Arbutus Biopharma ABUS Stock Holding History

Quinn Opportunity Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.32M	Hold	514,513	–	–	0.12%	146
2025 Q4	$2.47M	Hold	514,513	–	–	0.1%	161
2025 Q3	$2.34M	Buy	514,513 +50,000	+11%	+$184K	0.17%	127
2025 Q2	$1.44M	Hold	464,513	–	–	0.12%	160
2025 Q1	$1.62M	Buy	464,513 +59,634	+15%	+$199K	0.11%	180
2024 Q4	$1.32M	Buy	404,879 +169,747	+72%	+$624K	0.09%	176
2024 Q3	$905K	Buy	235,132 +70,000	+42%	+$269K	0.09%	149
2024 Q2	$510K	Buy	+165,132	New	+$495K	0.06%	174
2022 Q1	–	Sell	-276,485	Closed	-$1.08M	–	167
2021 Q4	$1.08M	Buy	+276,485	New	+$1.07M	0.07%	139

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Quinn Opportunity Partners's ABUS Position: Q1 2026 in Review

Quinn Opportunity Partners held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 514,513 shares worth $2.32M. The position accounts for 0.12% of the portfolio, ranked #146.

Quinn Opportunity Partners first reported a position in ABUS in Q4 2021 and has held it in 9 quarters since. The position peaked at $2.47M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Quinn Opportunity Partners held 514,513 shares of Arbutus Biopharma worth $2.32M as of Q1 2026.
Quinn Opportunity Partners left its Arbutus Biopharma share count unchanged in Q1 2026.
Arbutus Biopharma made up 0.12% of Quinn Opportunity Partners's portfolio in Q1 2026, its #146 holding.
Quinn Opportunity Partners first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 9 quarters since.
Quinn Opportunity Partners's Arbutus Biopharma position peaked at $2.47M in Q4 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.